<?xml version="1.0" encoding="UTF-8"?>
<!DOCTYPE article PUBLIC "-//NLM//DTD JATS (Z39.96) Journal Publishing DTD with MathML3 v1.1 20151215//EN" "JATS-journalpublishing1-mathml3.dtd">
<article dtd-version="1.1" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">
    <front>
        <journal-meta>
            <journal-id></journal-id>
            <issn></issn>
        </journal-meta>
        <article-meta>
            <title-group>
                <article-title></article-title>
            </title-group>
            <pub-date>
                <year></year>
            </pub-date>
        </article-meta> 
    </front>
    <back>
        <ref-list>
            <ref id="b1">
                <label>1. </label>
                <mixed-citation publication-type="journal">
                    <person-group person-group-type="author">
                        <name>
                            <surname>Yau</surname>
                            <given-names>JW</given-names>
                        </name>, 
                        <name>
                            <surname>Rogers</surname>
                            <given-names>SL</given-names>
                        </name>, 
                        <name>
                            <surname>Kawasaki</surname>
                            <given-names>R</given-names>
                        </name>, 
                        <name>
                            <surname>Lamoureux</surname>
                            <given-names>EL</given-names>
                        </name>, 
                        <name>
                            <surname>Kowalski</surname>
                            <given-names>JW</given-names>
                        </name>, 
                        <name>
                            <surname>Bek</surname>
                            <given-names>T</given-names>
                        </name>, 
                        <etal>et al</etal>; 
                        <collab>Meta-Analysis for Eye Disease (META-EYE) Study Group</collab>
                    </person-group>. 
                    <article-title>Global prevalence and major risk factors of diabetic retinopathy</article-title>. 
                    <source>Diabetes Care</source>. 
                    <year>2012</year>
                    <month>Mar</month>;
                    <volume>35</volume>(
                    <issue>3</issue>):
                    <fpage>556</fpage>–
                    <lpage>64</lpage>. 
                    <pub-id pub-id-type="doi">10.2337/dc11-1909</pub-id>
                    <pub-id pub-id-type="pmid">22301125</pub-id>
                    <issn>0149-5992</issn>
                </mixed-citation>
            </ref>
            <ref id="b2">
                <label>2. </label>
                <mixed-citation publication-type="journal">
                    <person-group person-group-type="author">
                        <collab>The Diabetic Retinopathy Study Research Group</collab>
                    </person-group>. 
                    <article-title>Photocoagulation treatment of proliferative diabetic retinopathy. Clinical application of Diabetic Retinopathy Study (DRS) findings, DRS Report Number 8</article-title>. 
                    <source>Ophthalmology</source>. 
                    <year>1981</year>
                    <month>Jul</month>;
                    <volume>88</volume>(
                    <issue>7</issue>):
                    <fpage>583</fpage>–
                    <lpage>600</lpage>.
                    <pub-id pub-id-type="pmid">7196564</pub-id>
                    <issn>0161-6420</issn>
                </mixed-citation>
            </ref>
            <ref id="b3">
                <label>3. </label>
                <mixed-citation publication-type="journal">
                    <person-group person-group-type="author">
                        <collab>Early Treatment Diabetic Retinopathy Study Research Group</collab>
                    </person-group>. 
                    <article-title>Early photocoagulation for diabetic retinopathy. ETDRS report number 9</article-title>. 
                    <source>Ophthalmology</source>. 
                    <year>1991</year>
                    <month>May</month>;
                    <volume>98</volume>(
                    <issue>5</issue>
                    <supplement>Suppl</supplement>):
                    <fpage>766</fpage>–
                    <lpage>85</lpage>. 
                    <pub-id pub-id-type="doi">10.1016/S0161-6420(13)38011-7</pub-id>
                    <pub-id pub-id-type="pmid">2062512</pub-id>
                    <issn>0161-6420</issn>
                </mixed-citation>
            </ref>
            <ref id="b4">
                <label>4. </label>
                <mixed-citation publication-type="book-chapter">
                    <person-group person-group-type="author">
                        <name>
                            <surname>Globočnik Petrovič</surname>
                            <given-names>M</given-names>
                        </name>, 
                        <name>
                            <surname>Lumi</surname>
                            <given-names>X</given-names>
                        </name>, 
                        <name>
                            <surname>Urbančič</surname>
                            <given-names>M</given-names>
                        </name>
                    </person-group>. 
                    <chapter-title>Vitrektomija</chapter-title>. In:
                    <person-group person-group-type="author">
                        <name name-style="western">
                            <surname>Cvenkel</surname>
                            <given-names>B</given-names>
                        </name>, 
                        <name> 
                            <surname>Debelić</surname>
                            <given-names>V</given-names>
                        </name>,
                        <name> 
                            <surname>Globočnik Petrovič</surname>
                            <given-names>M</given-names>
                        </name>,                        
                        
                        <name> 
                            <surname>Urbančič</surname>
                            <given-names>M</given-names>
                        </name>,
                        <etal>et al</etal>
                    </person-group>.                   
                    <source>Smernice za diagnostiko in zdravljenje diabetične retinopatije</source>. 
                    <publisher-loc>Ljubljana</publisher-loc>:
                    <publisher-name>Očesna klinika, Univerzitetni klinični center Ljubljana</publisher-name>;
                    <year>2017</year>. pp. 
                    <fpage>43</fpage>–
                    <lpage>9</lpage>.
                </mixed-citation>
            </ref>
            <ref id="b5">
                <label>5. </label>
                <mixed-citation publication-type="journal">
                    <person-group person-group-type="author">
                        <collab>The Diabetic Retinopathy Vitrectomy Study Group</collab>
                    </person-group>. 
                    <article-title>Two-year course of visual acuity in severe proliferative diabetic retinopathy with conventional management. Diabetic Retinopathy Vitrectomy Study (DRVS) report #1</article-title>. 
                    <source>Ophthalmology</source>. 
                    <year>1985</year>
                    <month>Apr</month>;
                    <volume>92</volume>(
                    <issue>4</issue>):
                    <fpage>492</fpage>–
                    <lpage>502</lpage>. 
                    <pub-id pub-id-type="doi">10.1016/S0161-6420(85)34002-2</pub-id>
                    <pub-id pub-id-type="pmid">4000644</pub-id>
                    <issn>0161-6420</issn>
                </mixed-citation>
            </ref>
            <ref id="b6">
                <label>6. </label>
                <mixed-citation publication-type="journal">
                    <person-group person-group-type="author">
                        <name>
                            <surname>Yan</surname>
                            <given-names>H</given-names>
                        </name>, 
                        <name>
                            <surname>Cui</surname>
                            <given-names>J</given-names>
                        </name>, 
                        <name>
                            <surname>Lu</surname>
                            <given-names>Y</given-names>
                        </name>, 
                        <name>
                            <surname>Yu</surname>
                            <given-names>J</given-names>
                        </name>, 
                        <name>
                            <surname>Chen</surname>
                            <given-names>S</given-names>
                        </name>, 
                        <name>
                            <surname>Xu</surname>
                            <given-names>Y</given-names>
                        </name>
                    </person-group>. 
                    <article-title>Reasons for and management of postvitrectomy vitreous hemorrhage in proliferative diabetic retinopathy</article-title>. 
                    <source>Curr Eye Res</source>. 
                    <year>2010</year>
                    <month>Apr</month>;
                    <volume>35</volume>(
                    <issue>4</issue>):
                    <fpage>308</fpage>–
                    <lpage>13</lpage>. 
                    <pub-id pub-id-type="doi">10.3109/02713680903572491</pub-id>
                    <pub-id pub-id-type="pmid">20373898</pub-id>
                    <issn>0271-3683</issn>
                </mixed-citation>
            </ref>
            <ref id="b7">
                <label>7. </label>
                <mixed-citation publication-type="journal">
                    <person-group person-group-type="author">
                        <name>
                            <surname>Aiello</surname>
                            <given-names>LP</given-names>
                        </name>, 
                        <name>
                            <surname>Avery</surname>
                            <given-names>RL</given-names>
                        </name>, 
                        <name>
                            <surname>Arrigg</surname>
                            <given-names>PG</given-names>
                        </name>, 
                        <name>
                            <surname>Keyt</surname>
                            <given-names>BA</given-names>
                        </name>, 
                        <name>
                            <surname>Jampel</surname>
                            <given-names>HD</given-names>
                        </name>, 
                        <name>
                            <surname>Shah</surname>
                            <given-names>ST</given-names>
                        </name>, 
                        <etal>et al</etal>
                    </person-group>.
                    <article-title>Vascular endothelial growth factor in ocular fluid of patients with diabetic retinopathy and other retinal disorders</article-title>. 
                    <source>N Engl J Med</source>. 
                    <year>1994</year>
                    <month>Dec</month>;
                    <volume>331</volume>(
                    <issue>22</issue>):
                    <fpage>1480</fpage>–
                    <lpage>7</lpage>. 
                    <pub-id pub-id-type="doi">10.1056/NEJM199412013312203</pub-id>
                    <pub-id pub-id-type="pmid">7526212</pub-id>
                    <issn>0028-4793</issn>
                </mixed-citation>
            </ref>
            <ref id="b8">
                <label>8. </label>
                <mixed-citation publication-type="journal">
                    <person-group person-group-type="author">
                        <name>
                            <surname>Nguyen</surname>
                            <given-names>QD</given-names>
                        </name>, 
                        <name>
                            <surname>Brown</surname>
                            <given-names>DM</given-names>
                        </name>, 
                        <name>
                            <surname>Marcus</surname>
                            <given-names>DM</given-names>
                        </name>, 
                        <name>
                            <surname>Boyer</surname>
                            <given-names>DS</given-names>
                        </name>, 
                        <name>
                            <surname>Patel</surname>
                            <given-names>S</given-names>
                        </name>, 
                        <name>
                            <surname>Feiner</surname>
                            <given-names>L</given-names>
                        </name>, 
                        <etal>et al</etal>; 
                        <collab>RISE and RIDE Research Group</collab>
                    </person-group>. 
                    <article-title>Ranibizumab for diabetic macular edema: results from 2 phase III randomized trials: RISE and RIDE</article-title>. 
                    <source>Ophthalmology</source>. 
                    <year>2012</year>
                    <month>Apr</month>;
                    <volume>119</volume>(
                    <issue>4</issue>):
                    <fpage>789</fpage>–
                    <lpage>801</lpage>. 
                    <pub-id pub-id-type="doi">10.1016/j.ophtha.2011.12.039</pub-id>
                    <pub-id pub-id-type="pmid">22330964</pub-id>
                    <issn>0161-6420</issn>
                </mixed-citation>
            </ref>
            <ref id="b9">
                <label>9. </label>
                <mixed-citation publication-type="journal">
                    <person-group person-group-type="author">
                        <name>
                            <surname>Heier</surname>
                            <given-names>JS</given-names>
                        </name>, 
                        <name>
                            <surname>Korobelnik</surname>
                            <given-names>JF</given-names>
                        </name>, 
                        <name>
                            <surname>Brown</surname>
                            <given-names>DM</given-names>
                        </name>, 
                        <name>
                            <surname>Schmidt-Erfurth</surname>
                            <given-names>U</given-names>
                        </name>, 
                        <name>
                            <surname>Do</surname>
                            <given-names>DV</given-names>
                        </name>, 
                        <name>
                            <surname>Midena</surname>
                            <given-names>E</given-names>
                        </name>, 
                        <etal>et al</etal>
                    </person-group>.
                    <article-title>Intravitreal Aflibercept for Diabetic Macular Edema: 148-Week Results from the VISTA and VIVID Studies</article-title>. 
                    <source>Ophthalmology</source>. 
                    <year>2016</year>
                    <month>Nov</month>;
                    <volume>123</volume>(
                    <issue>11</issue>):
                    <fpage>2376</fpage>–
                    <lpage>85</lpage>. 
                    <pub-id pub-id-type="doi">10.1016/j.ophtha.2016.07.032</pub-id>
                    <pub-id pub-id-type="pmid">27651226</pub-id>
                    <issn>0161-6420</issn>
                </mixed-citation>
            </ref>
            <ref id="b10">
                <label>10. </label>
                <mixed-citation publication-type="journal">
                    <person-group person-group-type="author">
                        <name>
                            <surname>Mehanna</surname>
                            <given-names>CJ</given-names>
                        </name>, 
                        <name>
                            <surname>Abdul Fattah</surname>
                            <given-names>M</given-names>
                        </name>, 
                        <name>
                            <surname>Haddad</surname>
                            <given-names>S</given-names>
                        </name>, 
                        <name>
                            <surname>Tamim</surname>
                            <given-names>H</given-names>
                        </name>, 
                        <name>
                            <surname>Ghazi</surname>
                            <given-names>N</given-names>
                        </name>, 
                        <name>
                            <surname>Salti</surname>
                            <given-names>H</given-names>
                        </name>
                    </person-group>. 
                    <article-title>Anti-VEGF Therapy for Persistent Neovascularization after Complete Panretinal Photocoagulation in Proliferative Diabetic Retinopathy</article-title>. 
                    <source>Ophthalmol Retina</source>. 
                    <year>2019</year>
                    <month>Jun</month>;
                    <volume>3</volume>(
                    <issue>6</issue>):
                    <fpage>473</fpage>–
                    <lpage>7</lpage>. 
                    <pub-id pub-id-type="doi">10.1016/j.oret.2019.02.001</pub-id>
                    <pub-id pub-id-type="pmid">31174668</pub-id>
                    <issn>2468-7219</issn>
                </mixed-citation>
            </ref>
            <ref id="b11">
                <label>11. </label>
                <mixed-citation publication-type="journal">
                    <person-group person-group-type="author">
                        <name>
                            <surname>El Annan</surname>
                            <given-names>J</given-names>
                        </name>, 
                        <name>
                            <surname>Carvounis</surname>
                            <given-names>PE</given-names>
                        </name>
                    </person-group>. 
                    <article-title>Current management of vitreous hemorrhage due to proliferative diabetic retinopathy</article-title>. 
                    <source>Int Ophthalmol Clin</source>. 
                    <year>2014</year>;
                    <volume>54</volume>(
                    <issue>2</issue>):
                    <fpage>141</fpage>–
                    <lpage>53</lpage>. 
                    <pub-id pub-id-type="doi">10.1097/IIO.0000000000000027</pub-id>
                    <pub-id pub-id-type="pmid">24613890</pub-id>
                    <issn>0020-8167</issn>
                </mixed-citation>
            </ref>
            <ref id="b12">
                <label>12. </label>
                <mixed-citation publication-type="journal">
                    <person-group person-group-type="author">
                        <name>
                            <surname>Jorge</surname>
                            <given-names>R</given-names>
                        </name>, 
                        <name>
                            <surname>Costa</surname>
                            <given-names>RA</given-names>
                        </name>, 
                        <name>
                            <surname>Calucci</surname>
                            <given-names>D</given-names>
                        </name>, 
                        <name>
                            <surname>Cintra</surname>
                            <given-names>LP</given-names>
                        </name>, 
                        <name>
                            <surname>Scott</surname>
                            <given-names>IU</given-names>
                        </name>
                    </person-group>. 
                    <article-title>Intravitreal bevacizumab (Avastin) for persistent new vessels in diabetic retinopathy (IBEPE study)</article-title>. 
                    <source>Retina</source>. 
                    <year>2006</year>
                    <month>Nov-Dec</month>;
                    <volume>26</volume>(
                    <issue>9</issue>):
                    <fpage>1006</fpage>–
                    <lpage>13</lpage>. 
                    <pub-id pub-id-type="doi">10.1097/01.iae.0000246884.76018.63</pub-id>
                    <pub-id pub-id-type="pmid">17151487</pub-id>
                    <issn>0275-004X</issn>
                </mixed-citation>
            </ref>
            <ref id="b13">
                <label>13. </label>
                <mixed-citation publication-type="journal">
                    <person-group person-group-type="author">
                        <name>
                            <surname>Figueira</surname>
                            <given-names>J</given-names>
                        </name>, 
                        <name>
                            <surname>Fletcher</surname>
                            <given-names>E</given-names>
                        </name>, 
                        <name>
                            <surname>Massin</surname>
                            <given-names>P</given-names>
                        </name>, 
                        <name>
                            <surname>Silva</surname>
                            <given-names>R</given-names>
                        </name>, 
                        <name>
                            <surname>Bandello</surname>
                            <given-names>F</given-names>
                        </name>, 
                        <name>
                            <surname>Midena</surname>
                            <given-names>E</given-names>
                        </name>, 
                        <etal>et al</etal>; 
                        <collab>EVICR.net Study Group</collab>
                    </person-group>. 
                    <article-title>Ranibizumab Plus Panretinal Photocoagulation versus Panretinal Photocoagulation Alone for High-Risk Proliferative Diabetic Retinopathy (PROTEUS Study)</article-title>. 
                    <source>Ophthalmology</source>. 
                    <year>2018</year>
                    <month>May</month>;
                    <volume>125</volume>(
                    <issue>5</issue>):
                    <fpage>691</fpage>–
                    <lpage>700</lpage>. 
                    <pub-id pub-id-type="doi">10.1016/j.ophtha.2017.12.008</pub-id>
                    <pub-id pub-id-type="pmid">29395119</pub-id>
                    <issn>0161-6420</issn>
                </mixed-citation>
            </ref>
            <ref id="b14">
                <label>14. </label>
                <mixed-citation publication-type="journal">
                    <person-group person-group-type="author">
                        <name>
                            <surname>Maturi</surname>
                            <given-names>RK</given-names>
                        </name>, 
                        <name>
                            <surname>Glassman</surname>
                            <given-names>AR</given-names>
                        </name>, 
                        <name>
                            <surname>Liu</surname>
                            <given-names>D</given-names>
                        </name>, 
                        <name>
                            <surname>Beck</surname>
                            <given-names>RW</given-names>
                        </name>, 
                        <name>
                            <surname>Bhavsar</surname>
                            <given-names>AR</given-names>
                        </name>, 
                        <name>
                            <surname>Bressler</surname>
                            <given-names>NM</given-names>
                        </name>, 
                        <etal>et al</etal>; 
                        <collab>Diabetic Retinopathy Clinical Research Network</collab>
                    </person-group>. 
                    <article-title>Effect of adding dexamethasone to continued ranibizumab treatment in patients with persistent diabetic macular edema: A DRCR network phase 2 randomized clinical trial</article-title>. 
                    <source>JAMA Ophthalmol</source>. 
                    <year>2018</year>
                    <month>Jan</month>;
                    <volume>136</volume>(
                    <issue>1</issue>):
                    <fpage>29</fpage>–
                    <lpage>38</lpage>. 
                    <pub-id pub-id-type="doi">10.1001/jamaophthalmol.2017.4914</pub-id>
                    <pub-id pub-id-type="pmid">29127949</pub-id>
                    <issn>2168-6165</issn>
                </mixed-citation>
            </ref>
            <ref id="b15">
                <label>15. </label>
                <mixed-citation publication-type="journal">
                    <person-group person-group-type="author">
                        <name>
                            <surname>Mekjavic</surname>
                            <given-names>PJ</given-names>
                        </name>, 
                        <name>
                            <surname>Kraut</surname>
                            <given-names>A</given-names>
                        </name>, 
                        <name>
                            <surname>Urbancic</surname>
                            <given-names>M</given-names>
                        </name>, 
                        <name>
                            <surname>Lenassi</surname>
                            <given-names>E</given-names>
                        </name>, 
                        <name>
                            <surname>Hawlina</surname>
                            <given-names>M</given-names>
                        </name>
                    </person-group>. 
                    <article-title>Efficacy of 12-month treatment of neovascular age-related macular degeneration with intravitreal bevacizumab based on individually determined injection strategies after three consecutive monthly injections</article-title>. 
                    <source>Acta Ophthalmol</source>. 
                    <year>2011</year>
                    <month>Nov</month>;
                    <volume>89</volume>(
                    <issue>7</issue>):
                    <fpage>647</fpage>–
                    <lpage>53</lpage>. 
                    <pub-id pub-id-type="doi">10.1111/j.1755-3768.2009.01740.x</pub-id>
                    <pub-id pub-id-type="pmid">19860774</pub-id>
                    <issn>1755-375X</issn>
                </mixed-citation>
            </ref>
            <ref id="b16">
                <label>16. </label>
                <mixed-citation publication-type="journal">
                    <person-group person-group-type="author">
                        <name>
                            <surname>Yang</surname>
                            <given-names>CS</given-names>
                        </name>, 
                        <name>
                            <surname>Hung</surname>
                            <given-names>KC</given-names>
                        </name>, 
                        <name>
                            <surname>Huang</surname>
                            <given-names>YM</given-names>
                        </name>, 
                        <name>
                            <surname>Hsu</surname>
                            <given-names>WM</given-names>
                        </name>
                    </person-group>. 
                    <article-title>Intravitreal bevacizumab (Avastin) and panretinal photocoagulation in the treatment of high-risk proliferative diabetic retinopathy</article-title>. 
                    <source>J Ocul Pharmacol Ther</source>. 
                    <year>2013</year>
                    <month>Jul-Aug</month>;
                    <volume>29</volume>(
                    <issue>6</issue>):
                    <fpage>550</fpage>–
                    <lpage>5</lpage>. 
                    <pub-id pub-id-type="doi">10.1089/jop.2012.0202</pub-id>
                    <pub-id pub-id-type="pmid">23495932</pub-id>
                    <issn>1080-7683</issn>
                </mixed-citation>
            </ref>
            <ref id="b17">
                <label>17. </label>
                <mixed-citation publication-type="journal">
                    <person-group person-group-type="author">
                        <name>
                            <surname>Sinawat</surname>
                            <given-names>S</given-names>
                        </name>, 
                        <name>
                            <surname>Rattanapakorn</surname>
                            <given-names>T</given-names>
                        </name>, 
                        <name>
                            <surname>Sanguansak</surname>
                            <given-names>T</given-names>
                        </name>, 
                        <name>
                            <surname>Yospaiboon</surname>
                            <given-names>Y</given-names>
                        </name>, 
                        <name>
                            <surname>Sinawat</surname>
                            <given-names>S</given-names>
                        </name>
                    </person-group>. 
                    <article-title>Intravitreal bevacizumab for proliferative diabetic retinopathy with new dense vitreous hemorrhage after full panretinal photocoagulation</article-title>. 
                    <source>Eye (Lond)</source>. 
                    <year>2013</year>
                    <month>Dec</month>;
                    <volume>27</volume>(
                    <issue>12</issue>):
                    <fpage>1391</fpage>–
                    <lpage>6</lpage>. 
                    <pub-id pub-id-type="doi">10.1038/eye.2013.200</pub-id>
                    <pub-id pub-id-type="pmid">24037235</pub-id>
                    <issn>0950-222X</issn>
                </mixed-citation>
            </ref>
            <ref id="b18">
                <label>18. </label>
                <mixed-citation publication-type="journal">
                    <person-group person-group-type="author">
                        <name>
                            <surname>Arevalo</surname>
                            <given-names>JF</given-names>
                        </name>, 
                        <name>
                            <surname>Lasave</surname>
                            <given-names>AF</given-names>
                        </name>, 
                        <name>
                            <surname>Wu</surname>
                            <given-names>L</given-names>
                        </name>, 
                        <name>
                            <surname>Maia</surname>
                            <given-names>M</given-names>
                        </name>, 
                        <name>
                            <surname>Diaz-Llopis</surname>
                            <given-names>M</given-names>
                        </name>, 
                        <name>
                            <surname>Alezzandrini</surname>
                            <given-names>AA</given-names>
                        </name>, 
                        <etal>et al</etal>; 
                        <collab>Pan-American Collaborative Retina Study Group (PACORES)</collab>
                    </person-group>. 
                    <article-title>Intravitreal Bevacizumab for Proliferative Diabetic Retionpathy: Results From the Pan-American Collaborative Retina Study Group (PACORES) at 24 Months of Follow-up</article-title>. 
                    <source>Retina</source>. 
                    <year>2017</year>
                    <month>Feb</month>;
                    <volume>37</volume>(
                    <issue>2</issue>):
                    <fpage>334</fpage>–
                    <lpage>43</lpage>. 
                    <pub-id pub-id-type="doi">10.1097/IAE.0000000000001181</pub-id>
                    <pub-id pub-id-type="pmid">27429384</pub-id>
                    <issn>0275-004X</issn>
                </mixed-citation>
            </ref>
            <ref id="b19">
                <label>19. </label>
                <mixed-citation publication-type="journal">
                    <person-group person-group-type="author">
                        <name>
                            <surname>Avery</surname>
                            <given-names>RL</given-names>
                        </name>, 
                        <name>
                            <surname>Pearlman</surname>
                            <given-names>J</given-names>
                        </name>, 
                        <name>
                            <surname>Pieramici</surname>
                            <given-names>DJ</given-names>
                        </name>, 
                        <name>
                            <surname>Rabena</surname>
                            <given-names>MD</given-names>
                        </name>, 
                        <name>
                            <surname>Castellarin</surname>
                            <given-names>AA</given-names>
                        </name>, 
                        <name>
                            <surname>Nasir</surname>
                            <given-names>MA</given-names>
                        </name>, 
                        <etal>et al</etal>
                    </person-group>.
                    <article-title>Intravitreal bevacizumab (Avastin) in the treatment of proliferative diabetic retinopathy</article-title>. 
                    <source>Ophthalmology</source>. 
                    <year>2006</year>
                    <month>Oct</month>;
                    <volume>113</volume>(
                    <issue>10</issue>):
                    <fpage>1695.e1</fpage>–
                    <lpage>15</lpage>. 
                    <pub-id pub-id-type="doi">10.1016/j.ophtha.2006.05.064</pub-id>
                    <pub-id pub-id-type="pmid">17011951</pub-id>
                    <issn>0161-6420</issn>
                </mixed-citation>
            </ref>
            <ref id="b20">
                <label>20. </label>
                <mixed-citation publication-type="journal">
                    <person-group person-group-type="author">
                        <name>
                            <surname>Parikh</surname>
                            <given-names>RN</given-names>
                        </name>, 
                        <name>
                            <surname>Traband</surname>
                            <given-names>A</given-names>
                        </name>, 
                        <name>
                            <surname>Kolomeyer</surname>
                            <given-names>AM</given-names>
                        </name>, 
                        <name>
                            <surname>VanderBeek</surname>
                            <given-names>BL</given-names>
                        </name>, 
                        <name>
                            <surname>Kim</surname>
                            <given-names>BJ</given-names>
                        </name>, 
                        <name>
                            <surname>Maguire</surname>
                            <given-names>AM</given-names>
                        </name>, 
                        <etal>et al</etal>
                    </person-group>.
                    <article-title>Intravitreal Bevacizumab for the Treatment of Vitreous Hemorrhage Due to Proliferative Diabetic Retinopathy</article-title>. 
                    <source>Am J Ophthalmol</source>. 
                    <year>2017</year>
                    <month>Apr</month>;
                    <volume>176</volume>:
                    <fpage>194</fpage>–
                    <lpage>202</lpage>. 
                    <pub-id pub-id-type="doi">10.1016/j.ajo.2017.01.010</pub-id>
                    <pub-id pub-id-type="pmid">28130042</pub-id>
                    <issn>0002-9394</issn>
                </mixed-citation>
            </ref>
            <ref id="b21">
                <label>21. </label>
                <mixed-citation publication-type="journal">
                    <person-group person-group-type="author">
                        <collab>Diabetic Retinopathy Clinical Research Network*</collab>
                    </person-group>. 
                    <article-title>Randomized clinical trial evaluating intravitreal ranibizumab or saline for vitreous hemorrhage from proliferative diabetic retinopathy</article-title>. 
                    <source>JAMA Ophthalmol</source>. 
                    <year>2013</year>
                    <month>Mar</month>;
                    <volume>131</volume>(
                    <issue>3</issue>):
                    <fpage>283</fpage>–
                    <lpage>93</lpage>. 
                    <pub-id pub-id-type="doi">10.1001/jamaophthalmol.2013.2015</pub-id>
                    <pub-id pub-id-type="pmid">23370902</pub-id>
                    <issn>2168-6165</issn>
                </mixed-citation>
            </ref>
            <ref id="b22">
                <label>22. </label>
                <mixed-citation publication-type="journal">
                    <person-group person-group-type="author">
                        <name>
                            <surname>Bhavsar</surname>
                            <given-names>AR</given-names>
                        </name>, 
                        <name>
                            <surname>Torres</surname>
                            <given-names>K</given-names>
                        </name>, 
                        <name>
                            <surname>Glassman</surname>
                            <given-names>AR</given-names>
                        </name>, 
                        <name>
                            <surname>Jampol</surname>
                            <given-names>LM</given-names>
                        </name>, 
                        <name>
                            <surname>Kinyoun</surname>
                            <given-names>JL</given-names>
                        </name>; 
                        <collab>Diabetic Retinopathy Clinical Research Network</collab>
                    </person-group>. 
                    <article-title>Evaluation of results 1 year following short-term use of ranibizumab for vitreous hemorrhage due to proliferative diabetic retinopathy</article-title>. 
                    <source>JAMA Ophthalmol</source>. 
                    <year>2014</year>
                    <month>Jul</month>;
                    <volume>132</volume>(
                    <issue>7</issue>):
                    <fpage>889</fpage>–
                    <lpage>90</lpage>. 
                    <pub-id pub-id-type="doi">10.1001/jamaophthalmol.2014.287</pub-id>
                    <pub-id pub-id-type="pmid">25010170</pub-id>
                    <issn>2168-6165</issn>
                </mixed-citation>
            </ref>
            <ref id="b23">
                <label>23. </label>
                <mixed-citation publication-type="journal">
                    <person-group person-group-type="author">
                        <name>
                            <surname>Sivaprasad</surname>
                            <given-names>S</given-names>
                        </name>, 
                        <name>
                            <surname>Prevost</surname>
                            <given-names>AT</given-names>
                        </name>, 
                        <name>
                            <surname>Bainbridge</surname>
                            <given-names>J</given-names>
                        </name>, 
                        <name>
                            <surname>Edwards</surname>
                            <given-names>RT</given-names>
                        </name>, 
                        <name>
                            <surname>Hopkins</surname>
                            <given-names>D</given-names>
                        </name>, 
                        <name>
                            <surname>Kelly</surname>
                            <given-names>J</given-names>
                        </name>, 
                        <etal>et al</etal>
                    </person-group>.
                    <article-title>Clinical efficacy and mechanistic evaluation of aflibercept for proliferative diabetic retinopathy (acronym CLARITY): a multicentre phase IIb randomised active-controlled clinical trial</article-title>.                     
                    <source>BMJ Open</source>. 
                    <year>2015</year>
                    <month>Sep</month>;
                    <volume>5</volume>(
                    <issue>9</issue>):
                    <fpage>e008405</fpage>–
                    <lpage>008405</lpage>. 
                    <pub-id pub-id-type="doi">10.1136/bmjopen-2015-008405</pub-id>
                    <pub-id pub-id-type="pmid">26369798</pub-id>
                    <issn>2044-6055</issn>
                </mixed-citation>
            </ref>
            <ref id="b24">
                <label>24. </label>
                <mixed-citation publication-type="journal">
                    <person-group person-group-type="author">
                        <name>
                            <surname>Gross</surname>
                            <given-names>JG</given-names>
                        </name>, 
                        <name>
                            <surname>Glassman</surname>
                            <given-names>AR</given-names>
                        </name>, 
                        <name>
                            <surname>Jampol</surname>
                            <given-names>LM</given-names>
                        </name>, 
                        <name>
                            <surname>Inusah</surname>
                            <given-names>S</given-names>
                        </name>, 
                        <name>
                            <surname>Aiello</surname>
                            <given-names>LP</given-names>
                        </name>, 
                        <name>
                            <surname>Antoszyk</surname>
                            <given-names>AN</given-names>
                        </name>, 
                        <etal>et al</etal>; 
                        <collab>Writing Committee for the Diabetic Retinopathy Clinical Research Network</collab>
                    </person-group>. 
                    <article-title>Panretinal Photocoagulation vs Intravitreous Ranibizumab for Proliferative Diabetic Retinopathy: A Randomized Clinical Trial</article-title>. 
                    <source>JAMA</source>. 
                    <year>2015</year>
                    <month>Nov</month>;
                    <volume>314</volume>(
                    <issue>20</issue>):
                    <fpage>2137</fpage>–
                    <lpage>46</lpage>. 
                    <pub-id pub-id-type="doi">10.1001/jama.2015.15217</pub-id>
                    <pub-id pub-id-type="pmid">26565927</pub-id>
                    <issn>0098-7484</issn>
                </mixed-citation>
            </ref>
            <ref id="b25">
                <label>25. </label>
                <mixed-citation publication-type="journal">
                    <person-group person-group-type="author">
                        <name>
                            <surname>Gross</surname>
                            <given-names>JG</given-names>
                        </name>, 
                        <name>
                            <surname>Glassman</surname>
                            <given-names>AR</given-names>
                        </name>, 
                        <name>
                            <surname>Liu</surname>
                            <given-names>D</given-names>
                        </name>, 
                        <name>
                            <surname>Sun</surname>
                            <given-names>JK</given-names>
                        </name>, 
                        <name>
                            <surname>Antoszyk</surname>
                            <given-names>AN</given-names>
                        </name>, 
                        <name>
                            <surname>Baker</surname>
                            <given-names>CW</given-names>
                        </name>, 
                        <etal>et al</etal>; 
                        <collab>Diabetic Retinopathy Clinical Research Network</collab>
                    </person-group>. 
                    <article-title>Five-Year Outcomes of Panretinal Photocoagulation vs Intravitreous Ranibizumab for Proliferative Diabetic Retinopathy: A Randomized Clinical Trial</article-title>. 
                    <source>JAMA Ophthalmol</source>. 
                    <year>2018</year>
                    <month>Oct</month>;
                    <volume>136</volume>(
                    <issue>10</issue>):
                    <fpage>1138</fpage>–
                    <lpage>48</lpage>. 
                    <pub-id pub-id-type="doi">10.1001/jamaophthalmol.2018.3255</pub-id>
                    <pub-id pub-id-type="pmid">30043039</pub-id>
                    <issn>2168-6165</issn>
                </mixed-citation>
            </ref>
            <ref id="b26">
                <label>26. </label>
                <mixed-citation publication-type="journal">
                    <person-group person-group-type="author">
                        <name>
                            <surname>Krick</surname>
                            <given-names>TW</given-names>
                        </name>, 
                        <name>
                            <surname>Bressler</surname>
                            <given-names>NM</given-names>
                        </name>
                    </person-group>. 
                    <article-title>Recent clinically relevant highlights from the Diabetic Retinopathy Clinical Research Network</article-title>. 
                    <source>Curr Opin Ophthalmol</source>. 
                    <year>2018</year>
                    <month>May</month>;
                    <volume>29</volume>(
                    <issue>3</issue>):
                    <fpage>199</fpage>–
                    <lpage>205</lpage>. 
                    <pub-id pub-id-type="doi">10.1097/ICU.0000000000000472</pub-id>
                    <pub-id pub-id-type="pmid">29528861</pub-id>
                    <issn>1040-8738</issn>
                </mixed-citation>
            </ref>
            <ref id="b27">
                <label>27. </label>
                <mixed-citation publication-type="journal">
                    <person-group person-group-type="author">
                        <name>
                            <surname>Hanna</surname>
                            <given-names>RM</given-names>
                        </name>, 
                        <name>
                            <surname>Barsoum</surname>
                            <given-names>M</given-names>
                        </name>, 
                        <name>
                            <surname>Arman</surname>
                            <given-names>F</given-names>
                        </name>, 
                        <name>
                            <surname>Selamet</surname>
                            <given-names>U</given-names>
                        </name>, 
                        <name>
                            <surname>Hasnain</surname>
                            <given-names>H</given-names>
                        </name>, 
                        <name>
                            <surname>Kurtz</surname>
                            <given-names>I</given-names>
                        </name>
                    </person-group>. 
                    <article-title>Nephrotoxicity induced by intravitreal vascular endothelial growth factor inhibitors: emerging evidence</article-title>. 
                    <source>Kidney Int</source>. 
                    <year>2019</year>
                    <month>Sep</month>;
                    <volume>96</volume>(
                    <issue>3</issue>):
                    <fpage>572</fpage>–
                    <lpage>80</lpage>. 
                    <pub-id pub-id-type="doi">10.1016/j.kint.2019.02.042</pub-id>; 
                    <pub-id pub-id-type="pmid">31229276</pub-id>
                    <issn>0085-2538</issn>
                </mixed-citation>
            </ref>
            <ref id="b28">
                <label>28. </label>
                <mixed-citation publication-type="journal">
                    <person-group person-group-type="author">
                        <name>
                            <surname>Obeid</surname>
                            <given-names>A</given-names>
                        </name>, 
                        <name>
                            <surname>Gao</surname>
                            <given-names>X</given-names>
                        </name>, 
                        <name>
                            <surname>Ali</surname>
                            <given-names>FS</given-names>
                        </name>, 
                        <name>
                            <surname>Talcott</surname>
                            <given-names>KE</given-names>
                        </name>, 
                        <name>
                            <surname>Aderman</surname>
                            <given-names>CM</given-names>
                        </name>, 
                        <name>
                            <surname>Hyman</surname>
                            <given-names>L</given-names>
                        </name>, 
                        <etal>et al</etal>
                    </person-group>.
                    <article-title>Loss to Follow-Up in Patients with Proliferative Diabetic Retinopathy after Panretinal Photocoagulation or Intravitreal Anti-VEGF Injections</article-title>. 
                    <source>Ophthalmology</source>. 
                    <year>2018</year>
                    <month>Sep</month>;
                    <volume>125</volume>(
                    <issue>9</issue>):
                    <fpage>1386</fpage>–
                    <lpage>92</lpage>. 
                    <pub-id pub-id-type="doi">10.1016/j.ophtha.2018.02.034</pub-id>
                    <pub-id pub-id-type="pmid">29606377</pub-id>
                    <issn>0161-6420</issn>
                </mixed-citation>
            </ref>
            <ref id="b29">
                <label>29. </label>
                <mixed-citation publication-type="journal">
                    <person-group person-group-type="author">
                        <name>
                            <surname>Obeid</surname>
                            <given-names>A</given-names>
                        </name>, 
                        <name>
                            <surname>Su</surname>
                            <given-names>D</given-names>
                        </name>, 
                        <name>
                            <surname>Patel</surname>
                            <given-names>SN</given-names>
                        </name>, 
                        <name>
                            <surname>Uhr</surname>
                            <given-names>JH</given-names>
                        </name>, 
                        <name>
                            <surname>Borkar</surname>
                            <given-names>D</given-names>
                        </name>, 
                        <name>
                            <surname>Gao</surname>
                            <given-names>X</given-names>
                        </name>, 
                        <etal>et al</etal>
                    </person-group>.
                    <article-title>Outcomes of Eyes Lost to Follow-up with Proliferative Diabetic Retinopathy That Received Panretinal Photocoagulation versus Intravitreal Anti-Vascular Endothelial Growth Factor</article-title>. 
                    <source>Ophthalmology</source>. 
                    <year>2019</year>
                    <month>Mar</month>;
                    <volume>126</volume>(
                    <issue>3</issue>):
                    <fpage>407</fpage>–
                    <lpage>13</lpage>. 
                    <pub-id pub-id-type="doi">10.1016/j.ophtha.2018.07.027</pub-id>
                    <pub-id pub-id-type="pmid">30077614</pub-id>
                    <issn>0161-6420</issn>
                </mixed-citation>
            </ref>
        </ref-list>
    </back>
</article>
